News
-
Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College will use a $500,000 grant from the New York State Biodefense Commercialization Fund for early development of a pentosan polysulfate (PPS) nasal spray for the… Read more . . .
-
TFF Pharmaceuticals announced that a Phase 1 SAD/MAD study of its dry powder niclosamide found that inhalation of the formulation was well tolerated at all doses evaluated and that data from the study suggest moving… Read more . . .
-
SK Bioscience announced that it has partnered with nonprofit research organization IAVI on development of an antiviral nasal spray based on a protein developed by David Baker at the University of Washington. The company noted… Read more . . .
-
Researchers from Northwestern University, the University of Washington, and Washington University at St. Louis have published data demonstrating that select miniproteins neutralized SARS-CoV-2 better than mAbs currently in use for the treatment of COVID-19. The… Read more . . .
-
The DDL committee is currently taking submissions for conference papers, for the Pat Burnell Young Investigator Award, and the DDL Emerging Scientist Award. To find complete guidelines for papers, the conference paper template, and the… Read more . . .
-
Receptor Life Sciences said that it has closed a $9.7 million Series A-1 financing and will use the proceeds for clinical development of its RLS103 cannabidiol DPI. RLS103 is based on MannKind Corporation’s Technosphere particle… Read more . . .
-
UK-based CDMO Upperton Pharma Solutions has launched a nasal delivery development platform called UpperNose, the company said. The UpperNose services include pre-formulation analyses, dosage form selection, and formulation and process development through to clinical trial… Read more . . .
-
The Lundquist Institute for Biomedical Innovation has announced that the Bill & Melinda Gates Foundation has awarded a 2-year grant of $471,858 to principal investigator Frans Walther for further development of an aerosolized synthetic lung surfactant… Read more . . .
-
Tiziana Life Sciences said that the FDA has issued a Study May Proceed letter allowing Brigham and Women’s Hospital (BWH) to treat an additional eight patients with secondary progressive multiple sclerosis (SPMS) with Tiziana’s intranasal… Read more . . .
-
Respira Therapeutics has announced the initiation of a Phase 2b trial of its RT234 dry powder vardenafil in patients with pulmonary arterial hypertension (PAH). The open label study will include two cohorts, with the first receiving a… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland